Propuesta apertura y gestión: Museo fiestas moros y cristianos oliva

[ES] Este proyecto pretende diseñar un museo sobre los Moros y Cristianos de Oliva, explicando las diferentes facetas y características de la fiesta para promocionarla turísticamente y preservar esta tradición centenaria. En primer lugar, se analizará la fiesta, sus orígenes, la normativa local y la evolución en los últimos años. Comentaremos las distintas fiestas locales. Para la recopilación de información se buscará en los archivos locales y se realizarán entrevistas a algunos expertos. Con la creación de este museo, lo que se va a intentar es mantener viva la esencia de una fiesta tan arraigada en este municipio. Para ello será interesante poder contar con las muchas técnicas de las que se dispone hoy en día. Para rememorar esta fiesta tradicional el museo organizará actividades lúdico-pedagógicas a través de las cuales se hará un breve recorrido por la historia.[EN] This Project aims to design a museum about the local celebration of "Moros y Cristianos" in Oliva, explaining different aspects and characteristics of the festival to promote it turistically and to preserve this century-old tradition. First will be analysed the celebration, its origins, its local regulations and its evolution in the last years. Then we will talk about other local celebrations. To gather information will be searched in local archives and some experts will be interviewed. With the creation of this museum, it will be kept the essence of this celebration, for this will be used the newest technology. The museum will do ludic pedagogical activities to recall the history of this celebration.Bertomeu Castello, J. (2020). Propuesta apertura y gestión: Museo fiestas moros y cristianos oliva. Universitat Politècnica de València. http://hdl.handle.net/10251/149658TFG

Apixaban versus warfarin in patients with atrial fibrillation

BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. RESULTS: The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P = 0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P = 0.42). CONCLUSIONS: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. Copyright © 2011 Massachusetts Medical Society. All rights reserved